Sunnypharmtech New Drug Development
505(B)2 PROJECTS
505(B)2 PROJECTS
Cancer Supportive Care: ASN-02
- ASN-02 is a 505(b)(2) new drug for cancer supportive cares, its therapeutic categories include Oral Mucositis, Radiation-induced acute dermatitis, chronic fibrosis, G.I. distress, cancer-related fatigue.
- More than 30 patents were granted worldwide covering cancer supportive care as well as other indications including anti-pruritus, skin disorders, joint destruction prevention, wound healing, etc.
- Phase II Clinical Study for CCRT-induced Oral Mucositis was completed.
- Flexible cooperative models will be adopted for commercialization.
研發進度如下所示:
ASN-02 SUPPORTIVE CANCER CARE| INDICATION | FORMULATION | DEVELOPMENT STAGE |
|---|---|---|
| CCRT1 CANCER THERAPY-INDUCED ORAL MUCOSITIS | ASN-020 2.5% ORAL RINSE | PHASE II |
| RADIATION-INDUCED ACUTE DERMATITIS | ASN-022 2.5% TOPICAL GEL | CLINICAL PROTOCOL FOR PHASE II |
| INDICATION | FORMULATION | DEVELOPMENT STAGE |
|---|---|---|
| PRURITUS | WYN 2.5% TOPICAL GEL | CLINICAL PROTOCOL FOR PHASE II |
| ROSACEA | WYN 2.5% TOPICAL GEL | CLINICAL PROTOCOL FOR PHASE II |